Clinical trials: Bladder Neoplasms
Bladder Cancer
Tumorspecific T-cell Immunity in Bladder Cancer as Prognostic Marker
Bladder cancer is generally susceptible to immunotherapeutic measures. The investigators will characterize 40 patients with muscle-invasive bladder cancer regarding the existence and frequency of tumorspecific T-cells and…
- Trial name
- NCT01198808
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
Muscle-invasive Bladder Urothelial Carcinoma
A Phase II Study of Toripalimab Plus RC48-ADC With Radiotherapy for Bladder Preservation in HER2-Positive Muscle-Invasive Bladder Cancer
This is a prospective, open-label, single-center, single-arm clinical study. Plans to enroll 45 MIBC patients with clinical stage T2-T4aN0M0 and HER2-positive (IHC 1+/2+/3+) status.
- Trial name
- NCT07279597
- Testing
- RC48-ADC + Toripalimab
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- Tongji Hospital
Bladder Cancer
Prediction of Impaired Survival in Elderly Bladder Cancer Patients Opting for Radical Cystectomy
The investigators proposes a prospective cohort study in patients with high risk bladder cancer who have opted for radical cystectomy.
- Trial name
- NCT02039310
- Where
- United States
- Volunteers
- 59 people
- Sponsor
- University of Michigan
Bladder Cancer
Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr Cancer
This is an open-label phase II study assessing the activity of cabozantinib combined with atezolizumab in patients with resectable muscle-invasive urothelial carcinoma who are ineligible for cisplatin-based therapy or decline…
- Trial name
- ABATE (NCT04289779)
- Testing
- Cabozantinib, Atezolizumab, Cystectomy
- Where
- 6 sites in United States
- Volunteers
- 46 people
- Sponsor
- Deepak Kilari
Poisoning by BCG Vaccine
Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects
The purpose of this study is to evaluate a possible role of intravesical Hyaluronic Acid in reducing local toxicity of Bacillus Calmette Guerin (BCG) used to treat bladder urothelial cell carcinoma.
- Trial name
- NCT02207608
- Testing
- Hyaluronic Acid, BCG (Immucist®)
- Volunteers
- 30 people
- Sponsor
- University of Rome Tor Vergata
Bladder Cancer
Study With a Newly Optical Coherence Tomography Probe for Optimizing Bladder Cancer Diagnosis and Treatment
The goal of this clinical trial is to see if a new designed optical coherence tomography catheter can be used in bladder cancer in patients undergoing a transurethral resection of a bladder tumour.
- Trial name
- BLOCT (NCT06679920)
- Testing
- Optical coherence tomography
- Where
- 2 sites in Netherlands
- Volunteers
- 15 people
- Sponsor
- Amsterdam UMC
Bladder Cancer
Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)
This study is being done to learn more about energy needs and muscle function during treatment for bladder cancer. These insights can help improve future patient care.
- Trial name
- METRICS (NCT06721260)
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- University of Kansas Medical Center
Urinary Stones, Prostate Cancer
Development of an AI-Agent for Urological Disease Diagnosis and Treatment
Urological diseases such as urinary stones, prostate cancer, and bladder cancer are very common and often require highly specialized diagnosis and treatment.
- Conditions
- Urinary Stones, Prostate Cancer, Bladder Cancer
- Trial name
- NCT07721935
- Where
- 3 sites in China
- Volunteers
- 2,000 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
Subjects will be randomized into 2 groups (stent or no stent) prior to radical cystectomy with ileal conduit urinary diversion (RCIC). They will follow the standard of care and be enrolled in the study for 12 months post-op.
- Conditions
- Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma, Pelvic Malignancy
- Trial name
- NCT07234968
- Testing
- Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Thomas Jefferson University
Rectal Cancer
The Impact of Patient Positioning and Use of Belly Board on Small Bowel and Urinary Bladder Volume Irradiated in Patients Receiving Radiotherapy for Rectal Cancer: A Prospective Phase II Study
Radiotherapy has a significant impact on local control, disease free survival and overall survival in patients with rectal cancer T2, N1, M0 and T3-4, any N, M0.
- Trial name
- NCT01142713
- Testing
- Patient Position During Radiotherapy
- Where
- Israel
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Prostate Cancer (Localized), Urinary Incontinence (C61)
Total en Bloc Urethra Preservation at Robot-assisted Prostatectomy IDEAL Stage 2a
Prospective single-arm IDEAL stage 2a feasibility study of urethra-preserving RARP in localized prostate cancer.
- Trial name
- ToP-RAP (NCT07678489)
- Testing
- ToP-RAP
- Where
- 2 sites in Germany
- Volunteers
- 60 people
- Sponsor
- Sami-Ramzi Leyh-Bannurah
Bladder Cancer, Urethral Cancer
S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium
RATIONALE: Drugs used in chemotherapy, such as carboplatin, paclitaxel, gemcitabine, and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00055835
- Testing
- carboplatin, cisplatin, gemcitabine hydrochloride
- Where
- 92 sites in United States
- Volunteers
- 7 people
- Sponsor
- SWOG Cancer Research Network
Advanced Bladder Cancer
Enfortumab Vedotin With Radiation for Locally Advanced Bladder Cancer (CONSOLIDATE)
To learn if the combination of enfortumab vedotin plus radiation therapy could help to control the disease.
- Trial name
- NCT06434350
- Testing
- Enfortumab Vedotin, Radiation Therapy
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Carcinoma of Urinary Bladder, Invasive
Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer
The purpose of this study is to evaluate the safety of intravesical instillation of TC-3 Hydrogel disposable device for retention of mitomycin C chemotherapeutic drug in the urinary bladder.
- Trial name
- NCT01648010
- Testing
- TC-3 gel, TC-3 gel mixed with Mitomycin C (MMC)
- Where
- 3 sites in Israel
- Volunteers
- 7 people
- Sponsor
- UroGen Pharma Ltd.
Bladder Cancer
Hypofractionated IMRT With Concurrent Chemotherapy in Muscle-invasive Bladder Cancer (HIRACUM)
The purpose of this study is to investigate the side effects, quality of life, and treatment effects of concurrent chemo-hypofractionated intensity-modulated radiation therapy in bladder cancer.
- Trial name
- HIRACOM (NCT05453682)
- Testing
- hypo-IMRT
- Where
- South Korea
- Volunteers
- 53 people
- Sponsor
- Samsung Medical Center
Bladder Cancer
Urine VOC Investigation in Bladder Cancer Diagnosis
The goal of this study to investigate the volatile organic compounds (VOCs) in the urine samples of both healthy individual and bladder cancer patients, using gas chromatography - mass spectrometry.
- Trial name
- NCT05671289
- Testing
- analysis of urine volatile organic compounds
- Where
- China
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Bladder Cancer
Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer
This is a phase 2, single arm, open label trial to evaluate the rate of failure free survival at 2 years after start of chemoradiation with adjuvant nivolumab in adult subjects who undergo chemoradiation for localized bladder…
- Trial name
- NEXT (NCT03171025)
- Testing
- Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- University of Utah
Urothelial Bladder Cancer, Gastric Adenocarcinoma
Basket Trial Exploring the Efficacy and Safety of the Combination of Niraparib and Dostarlimab
Treatment will consist of a PARP inhibitor (niraparib) monotherapy priming period (cycle 0; 21 days); an anti-PD-1 antibody (Dostarlimab ; TSR-042) will then be added from C1D1 every 21 days in combination for the first 4 cycles…
- Conditions
- Urothelial Bladder Cancer, Gastric Adenocarcinoma, Gastro-oesophageal Adenocarcinoma, Head and Neck Cancer
- Trial name
- NIRADO (NCT04779151)
- Testing
- Dostarlimab, Niraparib
- Where
- France
- Volunteers
- 51 people
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Non-muscle Invasive Bladder Cancer
Clinical and Functional Consequences of Photodynamic Diagnosis (PDD) and Intravesical Instillation Therapy
The aim is to evaluate and compare treatment strategies for non-muscle invasive bladder cancer. Furthermore, the impact of intravesical instillations on bladder function will be examined by urodynamic examination both prior to…
- Trial name
- URODYN (NCT04943094)
- Testing
- Urodynamic examination
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- Aarhus University Hospital
Bladder Cancer
A Phase I, Two-phase, Crossover Study to Evaluate the Safety, Tolerability and Pharmacokinetics of APL-1501 ER Tablets
A two-phase study design will be used for this pilot study. In the first phase, a 2×2 crossover study will be used to evaluate the safety, tolerability and PK characteristic of APL-1202 and APL-1501 ER Tablets 3.
- Trial name
- NCT04601766
- Testing
- APL-1202+APL-1501 ER Tablets 3+APL-1501 ER Tablets 2, APL-1501 ER Tablets 3+APL-1202+APL-1501 ER Tablets 2
- Where
- Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Asieris Pharmaceuticals (AUS) Pty Ltd.